The Philippines National TB Program’s (NTP) laboratory network strategic plan (LNSP) aims to improve access to quality laboratory services, including establishing new facilities, adopting new diagnostic technologies, and strengthening the laboratory systems. The implementation of laboratory network (LNW) strengthening plans and the performance of the LNW require a comprehensive monitoring of activities to detect problems, document results (performance), and gather lessons from the process. However, many program managers find monitoring difficult to implement because of the lack of knowledge, skills, and operational support, especially for field visits. A contributing factor is management’s weak appreciation of the value of monitoring for program management and improvement. This document aims to provide guidance to health workers who are tasked with monitoring the LNW’s status and performance. In this document, we provide the readers with practical tips on how to monitor—from preparation, data collection, data management, and reporting to a list of indicators to guide data collection.
The director of the Department of Pharmacy, Medicines, and Diagnostics (DPMED) wishes to adopt suitable software to strengthen the registration system for medicines and other health products. Although computerization yields improvements in the management of regulatory information, its effectiveness will largely depend on the presence of adequate medicines registration procedures and the system’s overall compliance with regional and international standards. This rapid evaluation thus seeks to analyze and understand Benin’s regulatory information management system for medicines registration, make appropriate recommendations, and propose an action plan based on emerging outcomes.
The West Africa Regional HIV Pharmaceutical Management Information Dashboard is developed and implemented for fifteen focus West African countries for better management of HIV and AIDS commodities. The goal of the Dashboard is to capture, track, aggregate, and disseminate information about antiretroviral drugs (ARVs), rapid test kits (RTKs), and other HIV and AIDS commodities to support evidence-based decision making in the West Africa subregion. The Dashboard will assist focus countries and subregional organizations in improving forecasting, supply planning, and procurement to support the continuous availability of ARVs, RTKs, and other HIV- and AIDS-related commodities.
The goal of the OSPSIDA Dashboard is to capture, track, aggregate, and disseminate information about antiretroviral drugs (ARVs), rapid test kits (RTKs), and other HIV and AIDS commodities to support evidence-based decision making in the West Africa subregion. The Dashboard offers regional partners a platform through which they may easily share information on funding flows and stock-out risks. The data available on this platform will be used to inform decision making and assist in identifying solutions to mitigate risks in the short-, medium-, and long-term. This User Guide assists users to make entries into the OSPSIDA Dashboard smoothly. The user guide has step-by-step guidance on how to access the dashboard, enter information, and generate reports.
Practical Guide for the Quantification of Anti-TB Medicines: Guidelines for Quantification and Supply Planning for Procurement
This guide is intended to serve as a reference for national-level quanitification, forecasting, and supply planning to inform the procurement of anti-TB medicines in the Philippines. It provides practical guidance for program managers, technical staff, and other key personnel, outlining common considerations and best practices for quantification, and highlighting different methods. It also includes specific guidance for the collection, review, and analysis of data, as well as for building forecast assumptions. To aid in completing quantification exercises, this guide also includes instructions for using QuanTB—an electronic quantification and early warning system designed by SIAPS to improve procurement processes, ordering, and supply planning for TB treatment.
Guidelines for Redistribution of Excess and Near-Expiry Essential Medicines between Public Health Facilities in South Sudan
The increased shortages and stock-out of essential medicines have raised the need to understand the causes of medicine expiries and subsequently develop strategies for their prevention and management.The MOH has developed this document to empower health workers at all levels to redistribute medicines and supplies that are not needed or are about to expire. Therefore, the procedures presented in this document should be used as a guideline to manage and execute the redistribution of essential medicines by technical staff and health managers at health facilities and program levels.
Developing a CMS strategic plan can help align pharmaceutical supply chain objectives with overall public-sector health supply chain strategies. It can help ensure that health commodities are readily available to health facilities through an uninterrupted supply chain; minimize waste and losses; improve business and financial growth; and respond to changes in the supply chain, such as new technologies and emerging markets. In addition, advocating for and encouraging stakeholders to assess the medicine supply chain system can increase interest in generating additional technical, financial, and material resources for health care. Supply chain interventions can also contribute to improving rational medicine use and strengthening pharmaceutical regulation.
Guidance on Elements to Consider when Planning for the Integration of Oxytocin into the EPI Cold Chain
The purpose of this document is to provide guidance to national program managers who are considering integrating oxytocin into the EPI cold chain. It is intended for representatives from relevant offices of the Ministry of Health (MoH), such as Pharmacy, Central Medical Stores, and Maternal and Child Health, as well as other policy makers, stakeholders, and implementing partners.
This guidance document introduces the pharmaceutical management elements that must be considered to successfully integrate oxytocin into the EPI cold chain and outlines the steps that will help national program managers plan the integration processes and strategies. Integrating oxytocin into the EPI cold chain may affect several elements within the pharmaceutical management cycle, from distribution systems, inventory management, and logistics management information systems and reporting procedures to roles and responsibilities, health facility infrastructure, and monitoring and evaluation. Some elements of the pharmaceutical system are afterthoughts that are only considered when challenges arise during implementation. Taking into account all elements that will be impacted by integrating oxytocin into a supply chain will not only help identify issues but also address needed changes in standard operating procedures and at the various stages of the supply chain. It is important to consider each element and address it in the strategy and implementation plan to ensure that oxytocin integration into the EPI cold chain is successful.
With the shift from a disease landscape that focuses on the treatment of acute and short-term illnesses to one that faces an increasing burden of chronic diseases that may require life-long medicine use, the role of medicines in ensuring a healthy population is more important than ever.
However,even when medicines are available, patients may not take them as directed. In other words, they may not adhere to the treatment prescribed to them. This problem is surprisingly widespread. Several studies have estimated that in developed countries, only approximately 50% of patients who suffer from chronic diseases take their medicines as directed.
This document suggests a health systems strengthening (HSS) approach to addressing
medication adherence issues, with a particular emphasis on its application in low- and middle-income settings. Chapter 2 reviews the importance of considering health systems in improving medication adherence and introduces a system-based framework, while Chapters 3–5 discuss approaches, interventions, and activities that span the health system as described at the
macro, meso, and micro levels and provide implementation examples.
This guide provides national stakeholders and advocates with information and guidance to update the national EML to include a new commodity, a new indication, or a new formulation based on the available evidence and based on country need and disease burden. While the actors, timeline, and process may vary from country to country, this guide presents the broad steps involved in revising an EML for any health commodity. Additional resources and a glossary are included to provide supplemental information and to clarify key terms.
The primary goal of the SIAPS TB Core portfolio was to ensure the availability of quality pharmaceutical products and support […]
- Rapport de quantification des produits de la santé reproductive, maternelle, néonatale et infantile pour la période de janvier 2017 à décembre 2020
La présente activité avait pour objectif d’apporter un soutien au Ministère de la Santé et de l’Hygiène publique (MSHP) pour […]
Project dates: September 2012 – December 2016